ARA-290 (Cibinetide): What the Trials Show
ARA-290 (cibinetide) explained: an EPO-derived repair peptide studied for small fiber neuropathy, trial results, and regulatory status. Not medical advice.
Anonymous user report. Not medical advice. Peptides discussed are not FDA-approved for the uses described. Editorial process →
Short answer
ARA-290 (cibinetide) is an 11-amino-acid peptide derived from erythropoietin (EPO). It is designed to activate EPO's tissue-protective "innate repair receptor" without raising red blood cell counts. In a 28-day phase 2b trial of 64 people with sarcoidosis-related small nerve fiber loss (Culver et al., 2017), one dose increased corneal nerve fiber area vs placebo, a marker of nerve regrowth; pain improved in all groups including placebo, and the difference was not statistically significant. The FDA granted orphan designation for sarcoidosis neuropathic pain in 2011, but ARA-290 is not approved anywhere and long-term safety is unknown. Peptide Confessions does not publish dosing, timing, injection or sourcing guidance. Last reviewed: October 2026.
Related topics
related peptides:
community guides:
More confessions from the archive
Community Q&A
- Is ARA-290 FDA approved?
- No. It has orphan designation for sarcoidosis neuropathic pain but no approval.
- Does ARA-290 help neuropathy?
- A small 28-day trial showed nerve regrowth markers improved, but pain relief vs placebo was not statistically significant.
- Does this page give dosing advice?
- Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.
Anonymous first-hand reports plus sourced context — educational only, not medical advice. Editorial policy & corrections.